AP-238 is an opioid designer drug related to drugs such as azaprocin and bucinnazine, with around the same potency as morphine.

[2] It was first discovered in Italy in the 1960s but was never marketed,[3] subsequently appearing on the illicit market around 2020 and being detected in both Slovenia and the USA.

[4][5]

This analgesic-related article is a stub.

You can help Wikipedia by expanding it.